First Israel Mezzanine Investors

FIMI is the leading private equity firm in Israel with more than $2 billion in assets under management. Since its founding by Ishay Davidi in 1996, FIMI has successfully completed 78 investments, executed 48 exits, and raised five funds. By both local and global standards, FIMI’s performance is exceptional. Preqin, the alternative assets industry’s leading source of data and intelligence, ranks FIMI as one of the top funds worldwide in terms of long-term return for investors. FIMI uses its knowledge, experience and resources to invest wisely, create value in its portfolio companies and generate maximum returns for FIMI investors. FIMI leverages a solid, proven, clear investment strategy, unrivaled access to quality deal-flow, and exceptional in-house expertise to achieve superior results.

Gillon Beck

Senior Partner

CP

Chelly Pardo

Partner and CFO

14 past transactions

Kamada Ltd.

Post in 2019
Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology. Kamada's product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The Company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility. Kamada’s flagship product is Glassia®; an FDA approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein, for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use and stabilizer free augmentation treatment. Kamada has a strategic agreement with Baxter for US marketing, distribution and licensing of Glassia®. Kamada’s second generation AAT product is an inhaled (IH) version. This product is already in advanced stages of clinical development for the treatment of AAT Deficiency. Other potential indications for AAT (IV or IH) include bronchiectasis, cystic fibrosis, COPD as well as type-1 diabetes for which the Company started a clinical trial. In addition to its capabilities to manufacture specialty proteins, Kamada has developed a platform technology for the production of specific immunoglobulins (IgGs). Kamada's unique know-how and capabilities enable it to seek new business opportunities and offer a wide scope of pharma-oriented services, including: R&D of new biopharmaceuticals, large scale production of high quality biopharmaceuticals, formulation and aseptic filling, registration and marketing. Over the years Kamada has established its presence in the pharma industry worldwide. Kamada’s mission is to develop, manufacture and provide high quality, specialty pharmaceuticals to patients, in order to support better quality of life and save lives.

BIRD Aerosystems

Private Equity Round in 2018
Bird Aerosystems Ltd develops and markets airborne missile protection systems, airborne surveillance products, and information and observation solutions. It also provides aviation logistics services to commercial and governmental customers; installation design and certification services; and scheduled and unscheduled maintenance for narrow-body aircraft. The company was founded in 2001 and is based in Herzliya, Israel.

Aitech Defense Systems

Acquisition in 2018
Aitech Defense Systems, Inc. provides commercial and military embedded computing solutions for the defense, space, and other customers worldwide. The company offers power supplies, single board computers and general purpose processors, Ethernet switches, carrier cards and transition modules, peripheral I/O boards, remote I/O products, memory boards, PMC/XMC mezzanines, power supplies, and rugged subsystems; rugged enclosures; and rugged controller/data concentrator units. It also provides system integration and technical support services. Aitech Defense Systems, Inc. was founded in 1983 and is based in Chatsworth, California with an additional office in India.

Gal‑Shvav

Acquisition in 2021
Gal‑Shvav Group offers manufacturing, assembly, and integration services, along with R&D and engineering support. Gal‑Shvav Group specializes in the design, development, production, and assembly of optomechanical components and systems. We serve customers in both the civilian and provide technologically advanced, comprehensive solutions. The company is privately-owned and has earned an outstanding reputation over the last three decades, both in Israel and abroad. We continually seek new recruits with creative minds, who aspire to professional growth and achievement. If you have the potential and desire to work with customers from product concept through product delivery, Gal‑Shvav Group is looking for you.

Stern Engineering

Acquisition in 2019
Stern Engineering is committed to provide smart water delivery solutions that maximize water savings and points for LEED projects.

G4S Israel

Acquisition in 2016
G4S Israel (formerly Hashmira) is a security company employs about 7,500 people and its annual sales turnover is estimated at NIS 800 million with an EBITDA margin of about 10%. The company's CEO, Micky Adiv, who has been in the position since 2006, is expected to remain together with the rest of the senior management. The company is part of the global G4S group which, according to its website, operates in over 100 countries and employs more than 610,000 people.

EMET Computing

Acquisition in 2021
EMET Computing is a full-service solution provider specializing in Data-Center, Cloud and Information Technologies. Founded in 1984, EMET accumulated extensive knowledge and partnership in the entire stack of infrastructure technology. EMET Computing is a public company, traded on the Tel-Aviv stock exchange. With offices in Ramat-Gan, Rosh-Ha’ayin, Petach-Tikva, Haifa and Ashdod, worldwide distribution hubs and a workforce of 850, EMET Computing can meet the most demanding customer challenges. Their experts match the best architecture to their customer challenges, propose and deploy best of breed solutions accompanied by class-leading services by highly trained professionals

Ezon Exchange

Venture Round in 2000
eZoneXchange.com, a subsidiary of Sapiens International Corporation N.V., provides software solutions to market-makers of B2B e-marketplaces. eZoneXchange.com's mission is to help these e-marketplace makers integrate their IT systems with the IT systems of their customers and suppliers. eZoneXchange.com also offers end-to-end shipment management solutions for e-marketplace transactions.

Rafa Laboratories Ltd.

Acquisition in 2020
Rafa is an Israeli pharmaceutical company specializing in the marketing, manufacture and distribution of generic and generic drugs, prescription drugs and over-the-counter medicines as well as therapeutic products. As a leading healthcare company in Israel, they are committed to improving the health and quality of life of their people. Rafa operates according to Israeli and internal ethical rules and in accordance with local regulations on various issues related to the manufacture of drugs, distribution, marketing and sales.

Kamada Ltd.

Post in 2020
Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology. Kamada's product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The Company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility. Kamada’s flagship product is Glassia®; an FDA approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein, for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use and stabilizer free augmentation treatment. Kamada has a strategic agreement with Baxter for US marketing, distribution and licensing of Glassia®. Kamada’s second generation AAT product is an inhaled (IH) version. This product is already in advanced stages of clinical development for the treatment of AAT Deficiency. Other potential indications for AAT (IV or IH) include bronchiectasis, cystic fibrosis, COPD as well as type-1 diabetes for which the Company started a clinical trial. In addition to its capabilities to manufacture specialty proteins, Kamada has developed a platform technology for the production of specific immunoglobulins (IgGs). Kamada's unique know-how and capabilities enable it to seek new business opportunities and offer a wide scope of pharma-oriented services, including: R&D of new biopharmaceuticals, large scale production of high quality biopharmaceuticals, formulation and aseptic filling, registration and marketing. Over the years Kamada has established its presence in the pharma industry worldwide. Kamada’s mission is to develop, manufacture and provide high quality, specialty pharmaceuticals to patients, in order to support better quality of life and save lives.

Ginegar

Private Equity Round in 2005
Ginegar Plastic Products, which produces and markets polyethylene sheets and nets for a variety of uses in agriculture and industry. Ginegar Plastic Products is a producer of advanced films for a wide variety of agricultural applications, with special emphasis on greenhouse covers, mulches, VIF films and also a range of non-agricultural applications.

Plastopil Ltd.

Acquisition in 2018
Plastopil develops, manufactures and markets an extensive array of flexible barrier films and technologically advanced packaging solutions that optimize the shelf-life and presentation of chilled foods. Over five decades, Plastopil has gained vast market experience, technological expertise, and a worldwide reputation for quality, integrity and service.
Orbit Technologies Ltd. provides airborne communications, and satellite-tracking maritime and ground-station solutions in Israel and internationally. It provides airborne, maritime, and rail mobile satcom products; and tracking and telemetry products, including aeronautical test telemetries and antenna control units. The company also offers EO satellite tracking and pedestals ground station solutions; and airborne audio solutions. In addition, it provides turnkey solutions. The company was founded in 1950 and is headquartered in Netanya, Israel.

PCB Technologies

Post in 2018
PCB Technologies Ltd. is a one-stop solution fabrication of high reliability, multilayer Printed Circuit Boards and top level assemblies (PCBA). Since 1981 They provide wide range of manufacturing solutions that meet the highest industry standards. Their focus is serving highly demanding markets such as: Defense, Aerospace, Medical, RF/Microwave, Telecom and more. Their highly-experienced staff, state-of-the-art technologies and advanced processes help deliver innovative solutions and ensure cost-effective fabrication of the most challenging and complex boards. PCB Technologies is a subsidiary of PriorTech Group and is traded on the Tel-Aviv Stock Exchange (symbol. PCBT). The company currently occupies 17,000 square meter in an advanced manufcaturing facility and employs a staff of 700 with an annual turnover of around $100 million. PCB Technologies' one-stop-shop for CEM services – from design to complete production, including full turnkey capabilities.